| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 06 Nov 2026 |
Form 4: Kiai Parsa, Director
Bought 661 shares ($8.61K) |
| 30 Oct 2026 |
Form 4: Kiai Parsa, Director
Bought 5,557 shares ($68K) |
| 26 Oct 2026 | 10-Q |
| 26 Oct 2026 |
8-K: Results of Operations and Financial Condition
BALTIMORE – (BUSINESS WIRE) — Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, today reported results for the third quarter ended September 30, ... |
| 30 Sep 2026 |
Form 4: Chard Daniel R, Director
Sold 9,545 shares ($114K) · Sold 9,544 shares ($112K) |
| 29 Sep 2026 | 144 |
| 28 Sep 2026 | 144 |
| 28 Aug 2026 |
Form 4: Kiai Parsa, Director
Bought 43,150 shares ($529K) |
| 26 Aug 2026 |
Form 4: Kiai Parsa, Director
Bought 4,329 shares ($51.9K) |
| 21 Aug 2026 | SCHEDULE 13D/A |
| 21 Aug 2026 |
Form 4: Kiai Parsa, Director
Bought 29,337 shares ($342K) · Bought 43,150 shares ($501K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 03 Aug 2026 | S-8 |
| 03 Aug 2026 | 10-Q |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
BALTIMORE – (BUSINESS WIRE) — Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter ended June 30, 2026. |
| 29 Jul 2026 | SCHEDULE 13G/A |
| 17 Jul 2026 |
8-K: Regulation FD Disclosure
The leading health and wellness company unveils an evolutionary transformation from weight loss to optimal metabolic health, powered by breakthrough science and human connection |
Loading...